# 2025-08824: FDA Starts Public Discussion on the Next Drug Fee Renewal

2025-08824, Reauthorization of the Prescription Drug User Fee Act; Public Meeting; Request for Comments, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2025-05-19, effective The hybrid public meeting will be held on July 14, 2025, from 9 a.m. to 2 p.m.; electronic or written comments must be submitted by August 14, 2025.; PRIA reads it as touching household money (as of 2026-10-21).

- Canonical: https://policyrisk.com/federal-register/2025-08824
- As of: 2026-10-21
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2025-08824
- Title: Reauthorization of the Prescription Drug User Fee Act; Public Meeting; Request for Comments
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 90 FR 21315
- Published: 2025-05-19
- Effective: The hybrid public meeting will be held on July 14, 2025, from 9 a.m. to 2 p.m.; electronic or written comments must be submitted by August 14, 2025.
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-10-21

## In one line

FDA Starts Public Discussion on the Next Drug Fee Renewal

## Summary

The FDA is gearing up to renew the Prescription Drug User Fee Act (PDUFA) for 2028-2032, which lets them collect fees to speed up drug reviews. This affects drug makers and patients waiting for new medicines. They’re hosting a public meeting on July 14, 2025, and want your thoughts by August 14, 2025, to help shape the future—and keep the money flowing smoothly.

## Abstract

The Food and Drug Administration (FDA, the Agency, or we) is hosting a public meeting to discuss proposed recommendations for the reauthorization of the Prescription Drug User Fee Act (PDUFA) for fiscal years (FYs) 2028 through 2032. PDUFA authorizes FDA to collect user fees to support the process for the review of human drug applications. The current legislative authority for PDUFA expires in September 2027. At that time, new legislation will be required for FDA to continue collecting prescription drug user fees in future fiscal years. The Federal Food, Drug, and Cosmetic Act (FD&C Act) directs that FDA begin the PDUFA reauthorization process by publishing a notice in the Federal Register requesting public input and holding a public meeting where the public may present its views on the reauthorization. FDA invites public comment as the Agency begins the process to reauthorize the program in FYs 2028 through 2032. These comments will be published and available on FDA's website.

## Effects PRIA read

- PDUFA Authority Expires September 2027: mixed, medium. You should know the current law that lets FDA collect prescription drug user fees expires in September 2027. The FDA says that without new legislation after that date it will no longer be able to collect those fees that support human drug reviews; the Agency is holding a public meeting on July 14,…
- Possible Changes to PDUFA Fee Structures: mixed, medium. FDA is requesting input on whether to change the current fee structures and amounts that fund the prescription drug user fee program. If fee structures or amounts are changed in future reauthorization negotiations, companies that submit marketing applications could see their fee obligations altered.
- PDUFA VII Commitments Support New Therapies: benefit, medium. Under the current PDUFA VII (in effect through FY 2027), FDA committed resources and new programs to support review of cell and gene therapies, include allergenic extract products, add timelines for pre-approval review of certain postmarketing items, create two new meeting types (Type D and INTERAC…

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2025-08824 on federalregister.gov](https://www.federalregister.gov/documents/2025/05/19/2025-08824/reauthorization-of-the-prescription-drug-user-fee-act-public-meeting-request-for-comments)
- [2025-08824 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2025-05-19/pdf/2025-08824.pdf)

## Related
- [Previous: 2025-08823, Agency Information Collection Activities: Proposed Collection: Public Comment R…](https://policyrisk.com/federal-register/2025-08823)
- [Next: 2025-08825, Proposed Extension of Information Collection Request Submitted for Public Comme…](https://policyrisk.com/federal-register/2025-08825)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2025-08824 (as of 2026-10-21).
